Cargando…

Multiple Sclerosis Treatment in the COVID-19 Era: A Risk-Benefit Approach

The COVID-19 pandemic poses an ongoing global challenge, and several risk factors make people with multiple sclerosis (pwMS) particularly susceptible to running a severe disease course. Although the literature does report numerous articles on the risk factors for severe COVID-19 and vaccination resp...

Descripción completa

Detalles Bibliográficos
Autores principales: Immovilli, Paolo, Morelli, Nicola, Terracciano, Chiara, Rota, Eugenia, Marchesi, Elena, Vollaro, Stefano, De Mitri, Paola, Zaino, Domenica, Bazzurri, Veronica, Guidetti, Donata
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9036272/
https://www.ncbi.nlm.nih.gov/pubmed/35466211
http://dx.doi.org/10.3390/neurolint14020030
_version_ 1784693487210332160
author Immovilli, Paolo
Morelli, Nicola
Terracciano, Chiara
Rota, Eugenia
Marchesi, Elena
Vollaro, Stefano
De Mitri, Paola
Zaino, Domenica
Bazzurri, Veronica
Guidetti, Donata
author_facet Immovilli, Paolo
Morelli, Nicola
Terracciano, Chiara
Rota, Eugenia
Marchesi, Elena
Vollaro, Stefano
De Mitri, Paola
Zaino, Domenica
Bazzurri, Veronica
Guidetti, Donata
author_sort Immovilli, Paolo
collection PubMed
description The COVID-19 pandemic poses an ongoing global challenge, and several risk factors make people with multiple sclerosis (pwMS) particularly susceptible to running a severe disease course. Although the literature does report numerous articles on the risk factors for severe COVID-19 and vaccination response in pwMS, there is a scarcity of reviews integrating both these aspects into strategies aimed at minimizing risks. The aim of this review is to describe the risk of vulnerable pwMS exposed to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the issues related to the SARS-CoV-2 vaccine and to evidence possible future strategies in the clinical management of pwMS. The authors searched for papers on severe COVID-19 risk factors, SARS-CoV-2 vaccination and people with multiple sclerosis in support of this narrative literature review. We propose a multilevel strategy aimed at: the evaluation of risk factors for severe COVID-19 in people with multiple sclerosis, identifying the most appropriate vaccination schedule that is safe for people on disease-modifying drugs (DMDs) and a strict follow-up of high-risk people with multiple sclerosis to allow for the prompt administration of monoclonal antibodies to manage COVID-19 risks in this patient population.
format Online
Article
Text
id pubmed-9036272
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-90362722022-04-26 Multiple Sclerosis Treatment in the COVID-19 Era: A Risk-Benefit Approach Immovilli, Paolo Morelli, Nicola Terracciano, Chiara Rota, Eugenia Marchesi, Elena Vollaro, Stefano De Mitri, Paola Zaino, Domenica Bazzurri, Veronica Guidetti, Donata Neurol Int Review The COVID-19 pandemic poses an ongoing global challenge, and several risk factors make people with multiple sclerosis (pwMS) particularly susceptible to running a severe disease course. Although the literature does report numerous articles on the risk factors for severe COVID-19 and vaccination response in pwMS, there is a scarcity of reviews integrating both these aspects into strategies aimed at minimizing risks. The aim of this review is to describe the risk of vulnerable pwMS exposed to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the issues related to the SARS-CoV-2 vaccine and to evidence possible future strategies in the clinical management of pwMS. The authors searched for papers on severe COVID-19 risk factors, SARS-CoV-2 vaccination and people with multiple sclerosis in support of this narrative literature review. We propose a multilevel strategy aimed at: the evaluation of risk factors for severe COVID-19 in people with multiple sclerosis, identifying the most appropriate vaccination schedule that is safe for people on disease-modifying drugs (DMDs) and a strict follow-up of high-risk people with multiple sclerosis to allow for the prompt administration of monoclonal antibodies to manage COVID-19 risks in this patient population. MDPI 2022-04-15 /pmc/articles/PMC9036272/ /pubmed/35466211 http://dx.doi.org/10.3390/neurolint14020030 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Immovilli, Paolo
Morelli, Nicola
Terracciano, Chiara
Rota, Eugenia
Marchesi, Elena
Vollaro, Stefano
De Mitri, Paola
Zaino, Domenica
Bazzurri, Veronica
Guidetti, Donata
Multiple Sclerosis Treatment in the COVID-19 Era: A Risk-Benefit Approach
title Multiple Sclerosis Treatment in the COVID-19 Era: A Risk-Benefit Approach
title_full Multiple Sclerosis Treatment in the COVID-19 Era: A Risk-Benefit Approach
title_fullStr Multiple Sclerosis Treatment in the COVID-19 Era: A Risk-Benefit Approach
title_full_unstemmed Multiple Sclerosis Treatment in the COVID-19 Era: A Risk-Benefit Approach
title_short Multiple Sclerosis Treatment in the COVID-19 Era: A Risk-Benefit Approach
title_sort multiple sclerosis treatment in the covid-19 era: a risk-benefit approach
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9036272/
https://www.ncbi.nlm.nih.gov/pubmed/35466211
http://dx.doi.org/10.3390/neurolint14020030
work_keys_str_mv AT immovillipaolo multiplesclerosistreatmentinthecovid19eraariskbenefitapproach
AT morellinicola multiplesclerosistreatmentinthecovid19eraariskbenefitapproach
AT terraccianochiara multiplesclerosistreatmentinthecovid19eraariskbenefitapproach
AT rotaeugenia multiplesclerosistreatmentinthecovid19eraariskbenefitapproach
AT marchesielena multiplesclerosistreatmentinthecovid19eraariskbenefitapproach
AT vollarostefano multiplesclerosistreatmentinthecovid19eraariskbenefitapproach
AT demitripaola multiplesclerosistreatmentinthecovid19eraariskbenefitapproach
AT zainodomenica multiplesclerosistreatmentinthecovid19eraariskbenefitapproach
AT bazzurriveronica multiplesclerosistreatmentinthecovid19eraariskbenefitapproach
AT guidettidonata multiplesclerosistreatmentinthecovid19eraariskbenefitapproach